AuRx Inc., of Glen Burnie, Maryland, said on Wednesday that a phase I/II trial of its therapeutic vaccine for genital herpes was successful, with the vaccine preventing all signs and symptoms of the disease in as many as 43.5% of patients for at least 1 year.
In the Mexican trial, 62 men and women received either three or two injections of the vaccine. AuRx President Gary Calton told Reuters Health that the total dose administered to all patients was roughly the same. Those receiving the
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!